Cambridge life sciences spin-out Epigenetix raises $5.5m in series A.
Cambridge Epigenetix, a life sciences spin-out of Cambridge University, has raised $5.5m in its series A funding round led by New Science Ventures. Cambridge Enterprise, the commercialisation arm of the university, and Syncona Partners also joined the round.
The news follows the announcement that the spin-out appointed Fedja Bobanovic as its new chief executive in April 2014.
The spin-out, incorporated in 2012, is based on research by Shankar Balasubramanian, professor at Cambridge’s Department of Chemistry. It exploits discoveries around epigenetics…
